Answers are grounded in this paper and cite their sources.
Dementia prevalence is increasing worldwide, with Alzheimer’s disease (AD) being the most common type. Amyloid-beta (Aβ) aggregation is an early pathological event in AD. Although carotenoids have been shown in vitro to inhibit Aβ aggregation through antioxidant and anti-inflammatory effects, human evidence remains limited. Recently, blood-based biomarkers such as Aβ42/40 ratios, phosphorylated tau (p-tau181, p-tau217), and neurofilament light chain (NfL) have enabled assessment of AD-related pathology. We analyzed 770 participants from the 2024 Iwaki Health Promotion Project in Japan. The associations between circulating carotenoid levels (skin and blood) and blood AD-related biomarkers were examined using adjusted linear and nonlinear regression models in a cross-sectional design. Among participants under 60 years, those in the highest quartile of skin carotenoid levels had significantly higher Aβ42/40 ratios than those in the lowest quartile (β = 0.0024, 95% CI: 0.0003–0.0046). The magnitude of the association was comparable to the cross-sectional difference in Aβ42/40 ratio observed across approximately 4–8 years of age. Among the blood carotenoids measured, lutein and α-carotene were positively associated with Aβ42/40 ratios. In summary, higher circulating carotenoid levels were associated with more favorable Aβ profiles in individuals under 60 years.
No takes yet. Share an insight, caveat, or question.
Yamauchi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: